Elafibranor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Elafibranor: Investigational PPAR Agonist — Predicted New Indication: Amenorrhea
Note: No original indication data is available for this drug in the current evidence pack, so the title cannot follow the standard "From X to Y" format.
One-Sentence Summary
Elafibranor is a PPAR-α/δ dual agonist; no original approved indication or detailed mechanism-of-action data is currently available in this evidence pack. The TxGNN model predicts it may be effective for Amenorrhea, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure computational (knowledge-graph) prediction with no clinical or mechanistic evidence backing it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no data in evidence pack) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for elafibranor is not available. Based on the limited information in this evidence pack, elafibranor is classified as a PPAR-α/δ dual agonist. No original indication data, published literature, or clinical trial evidence is available to establish a link between this mechanism and amenorrhea, the hypothalamic-pituitary-ovarian axis, or menstrual cycle regulation.
The TxGNN score (0.999) reflects a knowledge-graph connection strength only — it does not encode or imply a specific biological pathway. At present, there is no experimental, mechanistic, or clinical support for this repurposing hypothesis; it is derived purely from model inference.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Currently no marketing authorizations recorded in Norway (drug not yet marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction relies solely on a TxGNN knowledge-graph score (Evidence Level L5), with no clinical trials, literature, or mechanistic data linking PPAR-α/δ agonism to amenorrhea. The drug is also not marketed in Norway, so no regulatory or real-world safety experience exists to draw on.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (blocking gap — required before any safety pre-assessment, per DG001)
- Detailed mechanism-of-action (MOA) data to assess mechanistic plausibility (per DG002)
- Confirmation of elafibranor's original approved indication(s), if any exist in other jurisdictions
- Preclinical or mechanistic studies linking PPAR-α/δ pathways to reproductive endocrinology or menstrual regulation
- Any observational or case-level clinical evidence before this candidate can advance beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.